170 related articles for article (PubMed ID: 34046603)
1. Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (M
Franco LS; Maia RC; Barreiro EJ
RSC Med Chem; 2021 Jan; 12(1):110-119. PubMed ID: 34046603
[TBL] [Abstract][Full Text] [Related]
2. On the search for COVID-19 therapeutics: identification of potential SARS-CoV-2 main protease inhibitors by virtual screening, pharmacophore modeling and molecular dynamics.
Hassan A; Arafa RK
J Biomol Struct Dyn; 2022 Oct; 40(17):7815-7828. PubMed ID: 33749545
[TBL] [Abstract][Full Text] [Related]
3. Virtual screening and structure-based 3D pharmacophore approach to identify small-molecule inhibitors of SARS-CoV-2 M
Elseginy SA
J Biomol Struct Dyn; 2022; 40(24):13658-13674. PubMed ID: 34676801
[TBL] [Abstract][Full Text] [Related]
4. Identification of a Putative SARS-CoV-2 Main Protease Inhibitor through In Silico Screening of Self-Designed Molecular Library.
Liu N; Yang Z; Liu Y; Dang X; Zhang Q; Wang J; Liu X; Zhang J; Pan X
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511149
[TBL] [Abstract][Full Text] [Related]
5. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
Hajbabaie R; Harper MT; Rahman T
Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
[TBL] [Abstract][Full Text] [Related]
6. Novel phosphatidylinositol 4-kinases III beta (PI4KIIIβ) inhibitors discovered by virtual screening using free energy models.
Colodette NM; Franco LS; Maia RC; Fokoue HH; Sant'Anna CMR; Barreiro EJ
J Comput Aided Mol Des; 2020 Oct; 34(10):1091-1103. PubMed ID: 32601839
[TBL] [Abstract][Full Text] [Related]
7. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
[TBL] [Abstract][Full Text] [Related]
8. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
[TBL] [Abstract][Full Text] [Related]
9. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors.
Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R
J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303
[TBL] [Abstract][Full Text] [Related]
10. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
[TBL] [Abstract][Full Text] [Related]
11. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study.
Das S; Sarmah S; Lyndem S; Singha Roy A
J Biomol Struct Dyn; 2021 Jun; 39(9):3347-3357. PubMed ID: 32362245
[TBL] [Abstract][Full Text] [Related]
12. Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M
Hicks EG; Kandel SE; Lampe JN
Bioorg Med Chem Lett; 2022 Jun; 66():128732. PubMed ID: 35427739
[TBL] [Abstract][Full Text] [Related]
13. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
Mandour YM; Zlotos DP; Alaraby Salem M
J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies.
Tatar G; Salmanli M; Dogru Y; Tuzuner T
J Biomol Struct Dyn; 2022 Oct; 40(17):7656-7665. PubMed ID: 33749547
[TBL] [Abstract][Full Text] [Related]
15. An integrated metabolomic and proteomic approach for the identification of covalent inhibitors of the main protease (M
Baron G; Borella S; Della Vedova L; Vittorio S; Vistoli G; Carini M; Aldini G; Altomare A
Talanta; 2023 Jan; 252():123824. PubMed ID: 36027618
[TBL] [Abstract][Full Text] [Related]
16. Identification of highly effective inhibitors against SARS-CoV-2 main protease: From virtual screening to in vitro study.
Wang H; Wen J; Yang Y; Liu H; Wang S; Ding X; Zhou C; Zhang X
Front Pharmacol; 2022; 13():1036208. PubMed ID: 36467060
[No Abstract] [Full Text] [Related]
17. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening of natural products inspired in-house library to discover potential lead molecules against the SARS-CoV-2 main protease.
Garg A; Goel N; Abhinav N; Varma T; Achari A; Bhattacharjee P; Kamal IM; Chakrabarti S; Ravichandiran V; Reddy AM; Gupta S; Jaisankar P
J Biomol Struct Dyn; 2023 Mar; 41(5):2033-2045. PubMed ID: 35043750
[TBL] [Abstract][Full Text] [Related]
19. Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and
Banerjee S; Yadav S; Banerjee S; Fakayode SO; Parvathareddy J; Reichard W; Surendranathan S; Mahmud F; Whatcott R; Thammathong J; Meibohm B; Miller DD; Jonsson CB; Dubey KD
J Chem Inf Model; 2021 Nov; 61(11):5469-5483. PubMed ID: 34666487
[TBL] [Abstract][Full Text] [Related]
20. In Silico Identification of New Anti-SARS-CoV-2 Main Protease (M
Onyango H; Odhiambo P; Angwenyi D; Okoth P
J Trop Med; 2022; 2022():3697498. PubMed ID: 36263438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
